Ankle-Foot Orthosis in Duchenne Muscular Dystrophy: A 4 year Experience in a Multidisciplinary Neuromuscular Disorders Clinic
- 308 Downloads
To assess Ankle-Foot-Orthosis (AFO) requirement and ambulation in Duchenne Muscular Dystrophy (DMD) patients seen over a period of 4 y at a multi-disciplinary Neuromuscular disorders clinic (NMD).
A study was conducted in university quaternary research hospital with DMD patients confirmed by MLPA (multiplex ligation – dependent probe amplification) method and were evaluated between January 2012 and December 2015. Their ambulatory status, detailed neurological and functional status were recorded. Requirement of AFOs was determined and provided.
In total 126 DMD children reported to the NMD clinic. Mean age at presentation was 7.6 y (range 2 to12 y, SD 2.1). Mean duration of illness at first evaluation was 3.4 y (range 0.5 to 10 y, SD 2.0). AFO’s were advised at a mean age of 8.5 y (range 7 to 12 y, SD 1.8). Fifty-nine patients were advised AFO as resting or walking splint. At last follow-up 113 patients were still ambulatory whereas 13 had become wheel chair bound. Out of 59 patients, 48 were still wearing AFOs and the remaining discontinued AFOs for various reasons.
Children with DMD require wearing of AFOs as resting or walking splint, mostly in first or early second decade of life. As there is some gap between onset of clinical signs and requirement of orthosis, follow-up preferably at a multidisciplinary clinic at regular intervals is desirable for timely intervention in the form of AFOs or other splints to prolong ambulatory status in these patients.
KeywordsDuchenne muscular dystrophy Ankle-foot-orthosis Locomotion
- 6.Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.Google Scholar
- 14.Alemdaroğlu I, Gür G, Bek N, et al. Is there any relationship between orthotic usage and functional activities in children with neuromuscular disorders? Prosthet Orthot Int. 2014;38:27–33.Google Scholar
- 20.Sackley C, Disler PB, Turner-Stokes L, Wade DT, Brittle N, Hoppitt T. Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database Syst Rev. 2009;(3):CD003908.Google Scholar
- 21.Rose KJ, Burns J, Wheeler DM, North KN. Interventions for increasing ankle range ofmotion in patientswith neuromuscular disease. Cochrane Database Syst Rev. 2010;(2):CD006973.Google Scholar
- 22.Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010;25:1116–29.Google Scholar
- 25.Bello L, Kesari A, Gordish-Dressman H, et al. Genetic modifiers of ambulation in the cooperative international neuromuscular research group Duchenne natural history study. Ann Neurol. 2015;77:684–96.Google Scholar
- 29.Roposch A, Scher DM, Mubarak S, Kotz R. Treatment of foot deformities in patients with Duchenne muscular dystrophy. [Article in German]. Z Orthop Ihre Grenzgeb. 2003;141:54–8.Google Scholar